Follow this link:

Panavance Therapeutics Announces Foundational Publication of Misetionamide (GP-2250) in Ovarian Cancer in the Journal, Cancer Medicine

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh